Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Lyell Immunopharma (LYEL – Research Report) today and set a price target of $4.00. The company’s shares opened today at $2.94.
Harrison covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Editas Medicine. According to TipRanks, Harrison has an average return of 7.9% and a 53.46% success rate on recommended stocks.
Currently, the analyst consensus on Lyell Immunopharma is a Moderate Buy with an average price target of $9.00.
See today’s best-performing stocks on TipRanks >>
LYEL market cap is currently $745.5M and has a P/E ratio of -2.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
Read More on LYEL:
